Tivozanib Completed Phase 2 Trials for Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00502307A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
NCT01297244A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma